Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mydecine Innovations Group Inc (OP: MYCOF ) 0.0037 UNCHANGED Streaming Delayed Price Updated: 3:23 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mydecine Innovations Group Inc < Previous 1 2 3 4 5 6 7 Next > InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Enters Common Share Subscription Agreement August 30, 2022 Via Investor Brand Network InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Private Placement; Interim Changes to Management and Board August 19, 2022 Via Investor Brand Network Mydecine Innovations Group Reports Q2 Financial Results And Management Updates August 16, 2022 After the resignation of several key board members on August 12, Mydecine Innovations Group (OTC: MYCOF) reported its financial results. For the period corresponding to the six months ended June 30,... Via Benzinga Mydecine Reports Financial Results For 2021 April 01, 2022 Via Benzinga Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change July 19, 2022 Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications. Via Benzinga InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Designs Family of MDMA Analogs, Files Full Patent Application July 19, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved June 17, 2022 Biotech company Mydecine Innovations Group (OTC: MYCOF) received FDA approval for their novel proprietary MYCO-001. This is the first clearance of the company’s drug product. Via Benzinga InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces First Clearance of MYCO-001 for Government-Funded Study June 17, 2022 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Releases Status Update, Announces New Member of the Board June 09, 2022 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence Product Safety American Billionaire Entrepreneurs Bet Millions on Psychedelics May 10, 2022 FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman... Via FinancialNewsMedia Exposures Product Safety Mydecine Announces 1-for-50 Reverse Stock Split April 14, 2022 The board of directors of Mydecine Innovations Group Inc. (OTCPK:MYCOF) voted in favor of completing a reverse stock split. With this action, the company will consolidate all issued and outstanding... Via Benzinga Why Psychedelics Could Soon Replace Antidepressants April 13, 2022 FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults... Via FinancialNewsMedia Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements April 12, 2022 Via Investor Brand Network PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Working to Capitalize on Psychedelics Therapeutics Market’s Growth April 08, 2022 Via Investor Brand Network Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More! April 06, 2022 It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. Via Benzinga Demand for Toad Venom Rises Along With the Booming Psychedelics Market March 30, 2022 FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 30, 2022 – Depression and anxiety affect millions around the world and the venom of a toad is the latest psychedelic... Via FinancialNewsMedia BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Moving to Become Trusted Source of Effective Medication-Based Treatments March 29, 2022 Via Investor Brand Network Exposures Product Safety PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces IRB Approval for Planned Smoking Cessation Study March 24, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers a Glimpse into its R&D Pipeline, Patent Strategies, and Clinical Trials at March Investor Conferences March 18, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Playing Pivotal Role in Renaissance of Psychedelics March 17, 2022 Via Investor Brand Network PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Strengthening Leadership Role in Psychedelics Space March 10, 2022 Via Investor Brand Network Topics Supply Chain Exposures Supply Chain BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Participation Schedule for March Investor Conferences March 03, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Pre-IND Meeting with FDA for Smoking Cessation Study March 01, 2022 Via Investor Brand Network Exposures Product Safety Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005 February 28, 2022 Via Investor Brand Network InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Addresses Its ‘A to Z’ Approach to Drug Development in New Video February 24, 2022 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics February 23, 2022 Via Investor Brand Network PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs February 16, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Distinctive with Phased Approach to Novel Therapeutics Development February 15, 2022 Via Investor Brand Network Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience February 15, 2022 Via Investor Brand Network Topics Supply Chain Exposures Supply Chain Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th February 09, 2022 The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,... Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
